China CDC rules out animal virus spillover, Wuhan strain in Beijing COVID-19 outbreak

Source: Xinhua| 2020-06-27 10:24:33|Editor: huaxia

Staff members hold inactivated samples for nucleic acid test at the laboratory of KingMed Diagnostics, a Chinese medical diagnostic testing company in Beijing, capital of China, June 25, 2020. (Xinhua/Ju Huanzong)

BEIJING, June 27 (Xinhua) -- The Chinese Center for Disease Control and Prevention (CDC) on Friday said it has ruled out the possibility that the COVID-19 outbreak in Beijing is caused by a virus spillover from animals or the strain that previously circulated in the city of Wuhan.

In a report released on its website, the China CDC said massive tests indicated that the outbreak in Beijing is expected to be brought under control soon.

According to the report, a genetic analysis of samples from two COVID-19 patients and an environmental sample collected from the Xinfadi wholesale farm produce market showed that the virus is related to a European strain but is older than the one currently circulating in Europe.

The report said that cases linked to the market were most likely to have been infected through contact between persons, touch on contaminated surfaces of objects or both.

As the market has been closed since June 13, the risk of morbidity among people exposed to the site gets lower and lower, while all close contacts are being well managed, the report said.

Though a few cases with no connection with the Xinfadi market have recently been discovered, massive nucleic acid tests in Beijing showed that the infection rate among people who have no link to the market is extremely low, it added.

As Beijing has stepped up monitoring and social distancing measures, the risk of further spread is low, the report said.

A staff member takes reagent for nucleic acid test from an isolated windowsill used for delivery at the laboratory of KingMed Diagnostics, a Chinese medical diagnostic testing company in Beijing, capital of China, early June 26, 2020. (Xinhua/Ju Huanzong)

A staff member processes samples for nucleic acid test at the laboratory of KingMed Diagnostics, a Chinese medical diagnostic testing company in Beijing, capital of China, June 25, 2020. (Xinhua/Zhang Chenlin)

Staff members make preparations before processing samples for nucleic acid test at the laboratory of KingMed Diagnostics, a Chinese medical diagnostic testing company in Beijing, capital of China, June 25, 2020. (Xinhua/Zhang Chenlin)

Staff members put on protective suits before entering the laboratory of KingMed Diagnostics, a Chinese medical diagnostic testing company in Beijing, capital of China, late June 25, 2020. (Xinhua/Ju Huanzong)

Members of staff work at a COVID-19 testing lab built with an air-inflated structure in Daxing District, Beijing, capital of China, June 22, 2020. (Xinhua/Peng Ziyang)

Photo taken on June 22, 2020 shows a COVID-19 testing lab built with an air-inflated structure in Daxing District, Beijing, capital of China. (Xinhua/Peng Ziyang)

Members of staff work at a COVID-19 testing lab built with an air-inflated structure in Daxing District, Beijing, capital of China, June 22, 2020. (Xinhua/Peng Ziyang)

Residents wait in line to receive test at a nucleic acid testing site in Shoupakou South Street of Xicheng District, Beijing, capital of China, June 24, 2020. (Xinhua/Xing Guangli)

KEY WORDS:
EXPLORE XINHUANET
010020070750000000000000011102121391702601